|
 |
Ovine HyaluronidaseThis page contains recent news articles, when available, and an overview of Ovine Hyaluronidase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Vitrase Ovine (hyaluronidase injection) is a pure, preservative-free ovine hyaluronidase and is indicated as an adjuvant to "increase the absorption and ... OSN SuperSite … Injection of Vitrase (Ovine Hyaluronidase) Results in Improved... - Nov 4, 2005 ISTA's Vitrase(R) is a proprietary formulation of highly purified ovine hyaluronidase. In May 2004, the FDA approved Vitrase(R) in a lyophilized 6200 USP ... DG News … of ISTA's European Marketing Application for Ovine Hyaluronidase fo - Jan 12, 2006 Vitragan is ISTA's proprietary formulation of highly purified ovine hyaluronidase which is commonly known in the US as Vitrase(R). ... RedOrbit Vitrase (Hyaluronidase Injection) Now Available to US Ophthalmologists - Jan 6, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... DG News ISTA Pharmaceuticals Announces Publication of Vitrase Phase III... - Sep 7, 2005 ..."The study results suggest a therapeutic utility of ovine hyaluronidase in the management of vitreous hemorrhage," stated Lisa R. Grillone, Ph.D., ... $4.95 - PR Newswire - ECNext Press Release: ISTA Pharmaceuticals Announces Acceptance of ISTA's … - Jan 12, 2006 ISTA Pharmaceuticals Announces Acceptance of ISTA's European Marketing Application for Ovine Hyaluronidase for the Treatment of Vitreous Hemorrhage. from PR ... Pay-Per-View - PR Newswire - HighBeam Research ISTA Pharmaceuticals Announces VITRASE(R) Spreading Agent and … - Sep 19, 2005 ISTA's Vitrase(R) is a proprietary formulation of highly purified ovine hyaluronidase. In May 2004, the FDA approved Vitrase(R) in a lyophilized 6200 USP ... RedOrbit Simple Model Predicts Treatment Success With Vitrase(R) In Vitreous … - May 2, 2006 ISTA's Vitrase(R) is a proprietary formulation of highly purified ovine hyaluronidase. In May 2004, the FDA approved Vitrase(R) in a lyophilized 6200 USP ... Medical News Today - Medical News Today (press release) ISTA Pharmaceuticals Announces Xibrom(TM) and Vitrase(R) Clinical … - Apr 13, 2006 ISTA's Vitrase(R) (Ovine Hyaluronidase) is FDA-approved for use as a spreading agent, for hypodermoclysis, and as an adjunct in subcutaneous urography. ... Free with registration - PR Newswire - AccessMyLibrary.com Business & Finance; Vitrase maker presents clinical data at medical … - Oct 11, 2005 Ista's Vitrase is a formulation of highly purified ovine hyaluronidase. In May 2004, the FDA approved Vitrase in a lyophilized 6200 USP Units multi-purpose ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones ISTA Pharmaceuticals, Inc. Reports First Quarter 2006 Financial... - May 8, 2006 In January, ISTA announced the acceptance by the EMEA of ISTA's European Marketing Application for Vitragan(TM) (Ovine Hyaluronidase) for the treatment of ... $4.95 - PR Newswire - ECNext EU accepts ISTA's filing for Vitragan.(Ista Pharmaceuticals Inc.)(Brie... - Jan 23, 2006 Vitragan is ISTA's proprietary formulation of highly-purified ovine hyaluronidase which is commonly known in the USA as Vitrase. ... $4.95 - Pharma Marketletter - ECNext ISTA debuts Vitrase in USA.(Ista Pharmaceuticals Inc.)(Brief Article) - Jan 3, 2005 ISTA's Vitrase is a proprietary formulation of highly-purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Free with registration - Pharma Marketletter - AccessMyLibrary.com The authors respond. - Mar 1, 2007 The package insert for the new product, lyophilized ovine hyaluronidase (Vitrase[R]), states that the drug is an adjuvant indicated for increasing the ... Free with registration - Oncology Nursing Forum - AccessMyLibrary.com Press Release: ISTA Pharmaceuticals Announces VITRASE(R) … - Sep 19, 2005 ...(Ovine Hyaluronidase), which is currently FDA approved for use as a spreading agent for hypodermoclysis and as an adjunct in subcuteanous urography. ... Pay-Per-View - PR Newswire - HighBeam Research BSI, CAP, ERS, DAKT, DESC, ISTA Have Been Removed From Naked … - Jun 15, 2007 ...a formulation of ovine hyaluronidase for use as a Spreading agent; Vitragan for the treatment of Vitreous hemorrhage; and T-Pred for the treatment of ... $4.95 - M2 Presswire - ECNext International Approvals: Kivexa, Cumulase, Certican, and Others - Jan 6, 2005 The product is intended to replace the bovine and ovine hyaluronidase extracts currently used to strip away the hyaluronic acid sheath surrounding the ... Medscape ISTA, MEDI, PSDV, USEG, PPBL, TSSR Have Also Been Added To … - Jun 8, 2007 ...a formulation of ovine hyaluronidase for use as a Spreading agent; Vitragan for the treatment of Vitreous hemorrhage; and T-Pred for the treatment of ... $4.95 - M2 Presswire - ECNext Vesicant extravasation Part II: evidence-based management and … - Nov 1, 2006 Hyaluronidase was not commercially available for three years because its manufacture was discontinued, but lyophilized ovine hyaluronidase now is marketed ... Free with registration - Oncology Nursing Forum - AccessMyLibrary.com Press Release: ISTA Pharmaceuticals Launches Vitrase(R) in the United... - Jan 6, 2005 ISTA's Vitrase(R) is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in ... ... Pay-Per-View - PR Newswire - HighBeam Research Ophthalmic Conditions; FDA approves single-use vial of Vitrase for... - Jan 7, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Ophthalmic Conditions; US FDA approves single-use vial of Vitrase for... - Jan 15, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Ophthalmic Conditions; US FDA approves single-use vial of Vitrase for... - Jan 11, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: ISTA Pharmaceuticals Announces Xibrom(TM) and … - Apr 13, 2006 ISTA's Vitrase(R) (Ovine Hyaluronidase) is FDA-approved for use as a spreading agent, for hypodermoclysis, ... Read all of this article with a FREE trial ... Pay-Per-View - PR Newswire - HighBeam Research Hypodermoclysis; Vitrase launches in the United States - Jan 29, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Hypodermoclysis; Vitrase launches in the United States - Jan 24, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Hypodermoclysis; Vitrase launches in the United States - Jan 25, 2005 ISTA's Vitrase is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Ista Pharmaceuticals announces Phase III data demonstrating that a … - Oct 20, 2005 ...double-masked, placebo- controlled Phase III studies of Vitrase (Ovine Hyaluronidase) for the management of vitreous haemorrhage. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com ISTA Pharmaceuticals begins Vitrase shipments.(Two sizes offered) - Mar 1, 2005 Irvine, CA -- ISTA Pharmaceuticals has begun shipping units of pure ovine hyaluronidase for injection (Vitrase) in two sizes. ... Free with registration - Ophthalmology Times - AccessMyLibrary.com Clinical trials update: October 2005. - Nov 14, 2005 Inspire Denufosol P2Y2 receptor agonist Pharmaceuticals tetrasodium Inc. (ISPH) ISTA Vitrase Ovine hyaluronidase Pharmaceuticals (FDA- formulation Inc. ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com ISTA Pharmaceuticals Reports First Quarter 2005 Financial Results. - May 10, 2005 ...eye drop solution of timolol, a beta-blocking agent for the treatment of glaucoma and launched its second product, Vitrase(R) (ovine hyaluronidase), ... $4.95 - PR Newswire - ECNext Georgia Acts - ACT NO. 330 OF 2005 — SENATE BILL 89 - May 9, 2005 Olmesartain;" "(663.4) Omega-3-acid;" "(665.7) Ovine hyaluronidase;" "(692.54) Pemetrexed;" "(701.7) Pentetate zinc trisodium;" "(805.5) Prussian blue;" ... Pay-Per-View - Georgia Acts - Loislaw Press Release: ISTA Pharmaceuticals Reports First Quarter 2005 … - May 10, 2005 ...eye drop solution of timolol, a beta-blocking agent for the treatment of glaucoma and launched its second product, Vitrase(R) (ovine hyaluronidase), ... Pay-Per-View - PR Newswire - HighBeam Research FDA submissions, approvals and other actions: December 2004. - Jan 17, 2005 ISTA Vitrase Ovine hyaluronidase Pharmceuticals (FDA-approved) formulation Inc. (ISTA) PTC PTC124 Oral agent that targets Therapeutics nonsense mutations ... Pay-Per-View - Bioworld Financial Watch - Factiva, from Dow Jones ISTA Pharmaceuticals Reports Third Quarter 2005 Financial Results. - Nov 8, 2005 ...for Medicare and Medicaid Services(CMS) has granted two new national J-Codes covering the injection of preservative free ovine hyaluronidase, Vitrase. ... $4.95 - PR Newswire - ECNext Press Release: ISTA Pharmaceuticals Announces Phase III Data … - Oct 20, 2005 ...double-masked, placebo- controlled Phase III studies of Vitrase(R) (Ovine Hyaluronidase) for the management of vitreous hemorrhage, a serious condition ... Pay-Per-View - PR Newswire - HighBeam Research ISTA publishes Vitrase Ph II trial results.(Ista Pharmaceuticals... - Sep 12, 2005 ...headquartered in California, USA, has announced the publication of Phase II clinical trial results for its drug Vitrase (ovine hyaluronidase), ... $4.95 - Pharma Marketletter - ECNext Article: The physics behind the coating; Tool coatings have come a... - Mar 1, 2006 Article: Ovine hyaluronidase may induce PVD in diabetic eyes Ophthalmology Times; April 15, 2001 ; 700+ words ... ... may induce posterior vitreous ... Pay-Per-View - Fabricating & Metalworking - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |